FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Г										
	OMB APPROVAL									
ı	I									
l	OMB Number:	3235-0287								
l	Estimated average burden									
l	hours per response	: 0.5								

	Check this box if no longer subject
٦	to Section 16. Form 4 or Form 5
)	obligations may continue. See
	Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					01 360	JUOIT C	0(11)	ח נווכ	IIIVESIIII	CIII C	Ullipariy Act C	11340								
1. Name ar	2. Issuer Name and Ticker or Trading Symbol PLIANT THERAPEUTICS, INC. [PLRX									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)										
Counte										X	X Director 10% C				Owner					
(Loot)	-	•									X Officer (give title below)			Othe belov	r (specify					
(Last)	(Fi	RAPEUTICS, IN	/iddle))	3. Date of Earliest Transaction (Month/Day/Year) 07/14/2023									President and CEO						
260 LIT	4. If Amendment, Date of Original Filed (Month/Day/Year)								⁽⁾	6. Individual or Joint/Group Filing (Check Applicable Line)										
(Street)														X Form filed by One Reporting Person						
SOUTH	SAN														Form filed by More than One Reporting					
FRANC	(' /	A 9	4080)										Person						
					Rule 10b5-1(c) Transaction Indication															
(City)	(St	ate) (Z	Zip)		(,															
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													intended to	
		Table	I - N	on-Derivat	tive S	ecui	rities	Ac	quired	l, Di	sposed of	, or E	Benefi	ciall	ly Owr	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y					Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Acquire Disposed Of (D) (Instr. 5)				. 3, 4 and Secur Benef Owner		ties Fo cially (D I In		ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
										(A) or Dries			Following Reported Transaction(s)		(Instr. 4)					
									Code	ľ	Amount	(D)	" Pric	(Instr. 3						
Common Stock 07/14/202						23			A		137,500(1)	A	\$0	.00	412,253		D			
Common Stock															409,317		I		See footnote ⁽²⁾	
		Tab	le II	- Derivativ	ve Se	curit	ies A	Acq	uired,	Disp	osed of,	or Be	enefic	ially	Owne	d	,			
				(e.g., pu	ts, ca	lls, v	varra	ants	, optio	ns,	convertib	le se	curiti	es)						
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, if any			cution Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		De Se (In	Price of erivative ecurity str. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s ully	10. Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership (Instr. 4)	
				Code V (A) (D)		Date Exerci	Date Expiration Date		Title	Amoun or Numbe of Shares	r									
•	n of Respon	ses:																		
1 On July 20	2022 d. D.			1 27F 000 f					de la colonidad	f .	Actual Commission Control				of		ear a c	c		

- 1. On July 28, 2022, the Reporting Person was granted 275,000 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance July 14, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 137,500 shares.
- 2. Shares are held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose.

Remarks:

/s/ Mike Ouimette, attorney-07/18/2023 in-fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.